DYN - Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference | Benzinga
- Presentations will Highlight Initial Data Announced in January 2024 Demonstrating Proof-of-Concept in its DM1 and DMD Programs, Validating the Promise of the FORCE™ Platform and Targeted Delivery to Muscle -
- Additional Data from ACHIEVE and DELIVER Trials Expected in the Second Half of 2024 -
WALTHAM, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced two oral presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 3-6, 2024, in Orlando, Florida and virtually.
Both presentations will highlight the initial clinical data from the ACHIEVE and DELIVER trials reported by Dyne in January 2024. The initial clinical data from the ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) includes 6-month data from the 1.8 mg/kg (approximate ASO dose) cohort (n=16) and 3-month data from the 3.4 mg/kg Q4W cohort (n=16). Initial 6-month clinical data from the 5 mg/kg (approximate PMO dose) cohort (n=6) of the DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping will also be presented. Additionally, both presentations will include safety data from multiple cohorts in ACHIEVE and DELIVER trials which was shared in January.
"We're excited to present to the rare muscle disease community initial clinical data from our co-lead programs in DM1 and DMD, where there remains an urgent and significant need for new and better treatment options," said Wildon Farwell, M.D., MPH, chief medical officer of Dyne. "These data reinforce the potential of FORCE to deliver for patients, and we look forward to sharing additional clinical data from our ACHIEVE and DELIVER trials in the second half of this year."
Oral Presentations:
Abstract Title: Initial Data from the ACHIEVE Trial of DYNE-101 in Adults with Myotonic Dystrophy Type 1 (DM1)
Date and Time: Wednesday, March 6, 2024, at 10:15 a.m. ET
Presenter: Valeria Sansone, M.D., Ph.D., Clinical and Scientific Director, Clinical Center NeMO, Milan; Professor of Neurology, University of Milan and a Principal Investigator for the ACHIEVE Trial
Abstract Title: Initial Data from the DELIVER Trial of DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping
Date and Time: Wednesday, March 6, 2024, at 11:30 a.m. ET
Presenter: Kevin Flanigan M.D., Director, Center for Gene Therapy, Abigail Wexner Research Institute of Nationwide Children's Hospital in Columbus, Ohio and a Principal Investigator for the DELIVER Trial
The presentations will be available in the Scientific Publications & Presentations section of Dyne's website following the session.
About ACHIEVE
ACHIEVE is a Phase 1/2 global clinical trial evaluating DYNE-101, consisting of a 24-week multiple ascending dose (MAD) randomized placebo-controlled period, a 24-week open-label extension and a 96-week long-term extension. The trial, which is designed to be registrational, is enrolling adult patients with myotonic dystrophy type 1 (DM1) who are 18 to 49 years of age. The primary endpoints are safety and tolerability, with secondary endpoints ...